USD
EUR
GBP
CAD
AUD
CHF
HKD
JPY
RUB
BRL
CLP
NOK
DKK
SEK
KRW
ILS
MXN
CNY
SAR
SGD
NZD
ARS
INR
COP
AED
Home
Products
Peptides
Nootropics
Steriods
Sarms
Custom synthesis
Others
About Us
About Us
Sitemap
FAQ
Blog
News
Download
Contact Us
0
Home
Products
Peptides
Nootropics
Steriods
Sarms
Custom synthesis
Others
About Us
About Us
Sitemap
FAQ
Blog
News
Download
Contact Us
Home
>
News
News
AstraZeneca's 'semitinib' approved in China
May 09, 2023
05-09
2023
AstraZeneca's 'semitinib' approved in China,Company News
semitinib (AstraZeneca/Mercedon), binitinib (Pfizer/Pierre Fabre/Ono Pharmaceutical), cobimetinib (Roche/Exelixis), and trametinib (Japan Tobacco/Novartis)
Bayer's investigational small molecule 2023
May 08, 2023
05-08
2023
Bayer's investigational small molecule 2023
Runcaciguat (BAY 1101042) CAS: 1402936-61-1
Zabedosertib (BAY 1834845） CAS:1931994-81-8
Elinzanetant CAS: 929046-33-3
sarms4muscle-oxiracetam,piracetampowder products video
May 06, 2023
05-06
2023
sarms4muscle- oxiracetam ,piracetampowder products video
May 05, 2023
05-05
2023
New Small Molecule Drugs Approved by FDA in 2023Q1 and Drug Design Ideas
May 05, 2023
05-05
2023
New Small Molecule Drugs Approved by FDA in 2023Q1 and Drug Design Ideas
Brenzavvy (bexagliflozin)
Jayprica (Pirtobrutinib)
Orserdu (elacestrant)
Jesduvroq (daprodustat)
Filspari (sparsentan)
Skyclarys (omaveloxolone)
Zavzpret (zavegepant)
Daybue (trofinetide)
Rezzayo (rezafungin)
Joenja (leniolisib)
The Science Behind Aniracetam Capsules and Their Effects on the Brain
Apr 27, 2023
04-27
2023
JAK/HDAC bispecific inhibitor developed to be efficient against solid tumors and malignant leukemia
Apr 26, 2023
04-26
2023
JAK/HDAC bispecific inhibitor developed to be efficient against solid tumors and malignant leukemia
CBD replaces opioids for chronic pain
Apr 25, 2023
04-25
2023
The global medical cannabis market is expanding, and the treatment of chronic pain generates a large enough volume and demand for CBD products.
The epilepsy treatment drug: Cenobamate
Apr 24, 2023
04-24
2023
Chemical Name: Cenobamate
CAS No.: 913088-80-9
DAYBUE (Trofinetide) Approved by the FDA, Expected to Be Available at the End of Next Month.
Mar 31, 2023
03-31
2023
DAYBUE (trofinetide CAS 853400-76-7) approved by the FDA, expected to be available at the end of next month.
Rett, commonly known as Rett syndrome, is one of the most common genetic causes of severe mental impairment in the world.
Trofinetide is a new IGF-1 amino-terminal tripeptide analogue that is being developed to treat the main symptoms of Rett syndrome by lowering neuroinflammation and promoting synaptic function.
1
...
3
4
5
6
7
8
9
page:
Go
